Korea's Celltrion Completes Phase I Clinical Trials For Biosimilars Based On Roche And Johnson & Johnson Products
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korean biotech firm Celltrion said it has successfully completed Phase I clinical trials on its biosimilar versions of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade(infliximab)
You may also be interested in...
Biosimilars Aid Korea's Celltrion To Post Record Sales And Profit In FY 2010
SEOUL - South Korea's biosimilar front-runner Celltrion reported an all-time record high performance for sales and net profit in 2010, mainly from sales of its biosimilars of Roche's breast cancer agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis drug Remicade (infliximab) to countries in South America, the Middle East and Asia
Biosimilars Aid Korea's Celltrion To Post Record Sales And Profit In FY 2010
SEOUL - South Korea's biosimilar front-runner Celltrion reported an all-time record high performance for sales and net profit in 2010, mainly from sales of its biosimilars of Roche's breast cancer agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis drug Remicade (infliximab) to countries in South America, the Middle East and Asia
Korea's Celltrion To Supply Biosimilars To Europe And Japan This Year, Boosting Forecast
SEOUL - South Korea's biosimilar front-runner Celltrion said it would provide biosimilar products of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to Europe and Japan this year worth KRW 293 billion ($263.61 million)